Last updated: July 20, 2026
Novo Nordisk Inc. v. Aurobindo Pharma USA, Inc. (1:22-cv-00295): Litigation Summary, Patent Scope, and Generic Entry Risk
Novo Nordisk Inc. v. Aurobindo Pharma USA, Inc., case no. 1:22-cv-00295, is a U.S. patent litigation tied to Aurobindo’s FDA generic path for a Novo Nordisk-branded drug (identity and asserted patents are not determinable from the docket information provided). Without the asserted-claims record (complaint, counterclaims, claim chart, or Orange Book basis), the litigation cannot be accurately summarized in terms of specific patent numbers, filing paragraphs, claim constructions, remedies sought, or settlement terms.
What does Novo Nordisk’s lawsuit (1:22-cv-00295) allege and which patents are asserted?
Featured snippet answer: The asserted patent list and allegations are not available from the case identifier alone; a claim- and patent-specific summary cannot be produced.
What does the complaint typically include in Paragraph IV-style cases?
In Hatch-Waxman patent litigations, complaints usually specify:
- Asserted Orange Book patents (drug product, formulation, method-of-use, or manufacturing).
- Alleged infringement via the proposed generic product described in the ANDA notice.
- Requested relief (injunction, judgment of infringement, attorneys’ fees, costs).
- A “full” or “select” set of claims tied to the Orange Book listing date.
Which court and procedural posture matter for timelines?
A generic-infringement case generally turns on:
- Early scheduling: claim construction, summary judgment, and trial dates.
- Whether the case is resolved by dismissal, settlement, or an entry-triggering injunction.
- Whether stipulations narrow issues to specific patents/claims.
When does this litigation end and how does it affect generic launch timing?
Featured snippet answer: The effect on launch timing depends on the resolution date and whether the court grants or denies an injunction. The resolution timing cannot be derived from the docket number alone.
How does an injunction or stipulation change FDA exclusivity-to-entry sequencing?
Hatch-Waxman outcomes typically determine:
- Whether FDA approval is blocked during the 30-month stay window.
- Whether Aurobindo is permitted to launch at-risk if patents are found not infringed/invalid.
- Whether a settlement converts litigation into a payment-and-delay structure with an agreed launch date.
What are the common branching scenarios business teams track?
- Patents found infringed and valid: launch is blocked until expiration.
- Patents found invalid or not infringed: generic can launch at risk or after final appellate windows.
- Settlement: an agreed launch date and sometimes labeling carve-outs define market entry.
What is the Orange Book status of the Novo Nordisk product at issue in this case?
Featured snippet answer: Orange Book listing numbers and expiration dates are not identifiable without knowing the underlying FDA application/drug name.
What you must confirm from Orange Book to map patent exposure
A litigation summary normally includes:
- Drug product patent(s) and expiration dates.
- Formulation or method-of-use patents and expiration dates.
- Any pediatric exclusivity extensions.
- Any terminal disclaimers that truncate the effective term.
Which companies are challenging Novo Nordisk on the same drug and how does Aurobindo’s position compare?
Featured snippet answer: Comparable challengers cannot be listed without the drug identity and the asserted Orange Book patents.
How to benchmark Aurobindo’s risk relative to other ANDA filers
Once the drug is known, risk comparison typically uses:
- Whether other generics were first filers (earliest paragraph IV notices).
- Whether other defendants are litigating the same patent set.
- Whether courts stayed or consolidated issues across defendants.
What patent categories are likely at issue (product, formulation, method-of-use, manufacturing) and how do they change infringement analysis?
Featured snippet answer: Patent categories cannot be inferred from the case identifier alone.
How infringement theories diverge by patent type
- Drug substance/product patents: focus on identity, dosage form, and composition.
- Formulation patents: focus on excipients, particle size, polymorphs, and specific concentration ranges.
- Method-of-use patents: focus on labeling and instructed use, not composition alone.
- Manufacturing method patents: focus on process steps if the generic is made using a protected process.
What claim construction issues usually drive outcomes
Most cases turn on:
- Intrinsic evidence from specification.
- Whether a proposed generic meets each claim element literally or under doctrine of equivalents.
- Whether claim language is indefinite or lacks written description support.
What claims survived motions and what did the court decide on infringement/validity?
Featured snippet answer: The infringement and validity decisions are not accessible from the case identifier alone.
What outcomes should be summarized for a complete litigation analysis
A correct analysis includes:
- Motion-to-dismiss posture (if any).
- Claim construction rulings.
- Summary judgment decisions (invalidity, non-infringement, or no anticipation).
- Trial outcomes and post-trial findings.
- Any injunction scope and effective dates.
Has there been a settlement, stipulation, or dismissal in 1:22-cv-00295?
Featured snippet answer: Settlement terms and dismissal status cannot be determined without settlement/docket event data tied to the case record.
What settlement terms usually look like in this lane
When settlements occur, teams typically extract:
- Agreement to launch on a date certain.
- Dismissal without prejudice or with prejudice.
- Stipulated non-infringement for certain periods.
- Labeling commitments to avoid method-of-use triggers.
- Confidential terms that still influence real-world market entry.
What is the FDA and regulatory context for Aurobindo’s ANDA in this dispute?
Featured snippet answer: The ANDA number, FDA approval status, and regulatory pathway cannot be stated without the underlying drug identity and application details.
What FDA milestones are typically layered into litigation risk models
- ANDA submission date and acceptance.
- FDA filing status and tentative approval.
- Approval date (if any) and exclusivity overlays.
- 180-day exclusivity positions for first-filer generics.
- Risk of subsequent litigation over additional patents listed later in Orange Book.
How strong is Novo Nordisk’s patent estate in this matter and what does that imply for appeal risk?
Featured snippet answer: Strength cannot be assessed without the asserted patent numbers and their prosecution/claim scope.
What patent-strength analysis requires
In a defensible estate assessment, you normally see:
- Patent age and remaining term.
- Claim breadth (independent claim scope).
- Prior art landscape relevance (whether the case turns on narrow features).
- Prior invalidity rulings by other courts (if any).
- Potential enablement or written description vulnerabilities.
Generic entry risks for Aurobindo: what could allow or block launch notwithstanding litigation?
Featured snippet answer: Launch risks cannot be quantified without the litigation resolution and the Orange Book patent list.
Launch blockers that persist even after adverse rulings
- Remaining unasserted patents on the Orange Book.
- Additional patents added by amendment after initial notice.
- Labeling restrictions tied to method-of-use patents.
- Enforcement by related entities with continuation families.
Key Takeaways
- The case identifier (1:22-cv-00295) alone is insufficient to produce a patent-specific litigation summary.
- A complete, business-usable litigation analysis requires at least: drug identity, Orange Book patent numbers asserted, the court’s procedural milestones, and the case disposition.
- Without those inputs, any statement about infringement findings, injunction timing, settlement dates, or launch risk would not be accurate.
FAQs
- Does 1:22-cv-00295 involve a Paragraph IV notice, and what is the 30-month stay trigger?
- What patents are typically asserted by Novo Nordisk in Hatch-Waxman cases, and how do product vs method-of-use claims change the analysis?
- If there is a settlement, how is the permitted launch date usually determined and what labeling commitments are common?
- How do Orange Book patent additions after initial notice affect generic launch even if the first set is resolved?
- What litigation outcomes most often drive appeals and what is the practical impact on FDA approval timing?
References
- Docket identifier provided by user: Novo Nordisk Inc. v. Aurobindo Pharma USA, Inc., 1:22-cv-00295.
